Phase 2 COPD Trial, Recruiting NCT07646587 Sponsor: Windward Bio Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT07646587
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between the ages of 40 and 80
  • People whose breathing test results (taken after using an inhaler) show a specific pattern of reduced lung function, measured within a certain range (confirm with trial site for exact values)
  • People who have been using a stable combination of three inhaled lung medicines for at least 3 months
  • People who are former smokers with at least a 10 pack-year smoking history and who have not smoked for at least 6 months
  • People whose blood tests show an elevated level of a certain type of immune cell called eosinophils
  • People whose weight and body mass index (a measure of body size) fall within the range allowed by the trial

Who may not be able to join:

  • People with a significant lung condition other than COPD (chronic obstructive pulmonary disease)
  • People with serious other health conditions or active infections that the trial doctor believes could affect safety or how the study runs
  • People with significant heart or cardiovascular disease
  • People who have had a recent chest infection or a flare-up of their COPD
  • People who have recently used certain approved or experimental biologic medicines for COPD without enough time having passed since their last dose
  • People who are pregnant or breastfeeding
  • People who currently smoke or who have a diagnosed substance use disorder
  • People with any other condition or circumstance that the trial doctor believes would make participation unsafe or affect the reliability of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Omar Khwaja, MD, Windward Bio

Phone: +4161 551 75 75

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Windward Bio
Registry
ClinicalTrials.gov
Start date
2 June 2026
Est. completion
17 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with Adverse Events (AEs); Number of participants with Serious Adverse Events (SAEs); Change from baseline in systolic blood pressure (mmHg); Change from baseline in diastolic blood pressure (mmHg); Change from baseline in pulse rate (beats/minute); Change from baseline in respiratory rate (breaths/minute); Change from baseline in oxygen saturation (%); Change from baseline in body weight (kg); Change from baseline in body mass index (kg/m^2); Change from baseline in body temperature (°C); Change from baseline in clinical chemistry laboratory assessments; Change from bas...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov